Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy

Managing anticoagulation in hematological malignancy patients with atrial fibrillation and thrombocytopenia is a clinical challenge with limited data. We aimed to identify anticoagulation management strategies and evaluate bleeding and thrombosis rates associated with each approach. A retrospective...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2021-08, Vol.52 (2), p.590-596
Main Authors: Livneh, Nir, Braeken, Dionne, Drozdinsky, Genady, Gafter-Gvili, Anat, Seelig, Jaap, Rozovski, Uri, Berger, Tamar, Raanani, Pia, Falanga, Anna, ten Cate, Hugo, Spectre, Galia, Leader, Avi
Format: Article
Language:English
Subjects:
Aged
Anemia
Anticoagulants - adverse effects
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Bleeding
Cardiac arrhythmia
Cardiology
Fibrillation
Hematologic Neoplasms - complications
Hematologic Neoplasms - drug therapy
Hematology
Hemorrhage - chemically induced
Humans
Malignancy
Medicine
Medicine & Public Health
Multivariate analysis
Patients
Platelets
Retrospective Studies
Thrombocytopenia
Thrombocytopenia - chemically induced
Thrombocytopenia - drug therapy
Thromboembolism
Thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Managing anticoagulation in hematological malignancy patients with atrial fibrillation and thrombocytopenia is a clinical challenge with limited data. We aimed to identify anticoagulation management strategies and evaluate bleeding and thrombosis rates associated with each approach. A retrospective cohort study in Israel and the Netherlands was conducted. Patients with hematological malignancy and atrial fibrillation were indexed when platelets were 
ISSN:0929-5305
1573-742X
DOI:10.1007/s11239-021-02393-8